{"schema_version":"secwatch.filing_event.v1","accession":"0000898432-23-000037","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.395114+00:00","generated_at":"2026-06-20T01:59:19.481549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iRadimed Q4 revenue $14.9M (+25% YoY); declares special $1.05 dividend; FY23 guidance $61-63M","bullets":["Q4 2022 revenue $14.9M (vs $11.9M Q4 2021); GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.32.","Full-year 2022 revenue $53.3M (vs $41.8M FY2021); GAAP EPS $1.02; non-GAAP EPS $1.10.","Board declared special cash dividend of $1.05/share, payable Feb 21, 2023 to holders of record Feb 13, 2023.","FY 2023 guidance: revenue $61-63M, GAAP EPS $1.10-1.20, non-GAAP EPS $1.23-1.34; Q1 2023 revenue $14.6-14.9M.","Cash and equivalents $57.9M, no debt; gross margin 77.4% for full year 2022 (up from 76.6%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000898432-23-000037","json":"https://secwatch.observer/filing/0000898432-23-000037.json","markdown":"https://secwatch.observer/filing/0000898432-23-000037.md","text":"https://secwatch.observer/filing/0000898432-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:59:19.481549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bbf0721deb207c9ae1b5de9a46274321f8bc14a","claim":"IRADIMED CORP reported the twelve months ended December 31, 2022 results: revenue $53.3 million, net income $12.8 million, EPS $1.02 per diluted share. Guidance initiated.","evidence_excerpt":"For the twelve months ended December 31, 2022, the Company reported revenue of $53.3 million compared to $41.8 million for the same period in 2021. Net income was $12.8 million, or $1.02 per diluted share, compared to $9.3 million, or $0.74 per diluted share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2022"},{"label":"Revenue","value":"$53.3 million"},{"label":"Net income","value":"$12.8 million"},{"label":"EPS","value":"$1.02 per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5c373d9b5d5618fafd4d61d8508db8954ae82878","claim":"IRADIMED CORP reported full year 2023 results: revenue $61 million to $63 million, EPS $1.10 to $1.20 per diluted share (GAAP). Guidance initiated.","evidence_excerpt":"For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$61 million to $63 million"},{"label":"EPS","value":"$1.10 to $1.20 per diluted share (GAAP)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"5fef7e58b960e314b3c111da5ce9e8f19ea8817c","claim":"IRADIMED CORP reported first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS $0.23 to $0.25 per diluted share (GAAP). Guidance initiated.","evidence_excerpt":"For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$14.6 million to $14.9 million"},{"label":"EPS","value":"$0.23 to $0.25 per diluted share (GAAP)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ac4d695686e75372e31252fe198fd1fd6bf83a82","claim":"IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million, net income $3.7 million, EPS $0.29 per diluted share. Guidance initiated.","evidence_excerpt":"For the fourth quarter ended December 31, 2022, the Company reported revenue of $14.9 million compared to $11.9 million for the fourth quarter of 2021. Net income was $3.7 million, or $0.29 per diluted share, compared to $3.9 million, or $0.31 per diluted share, for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000089843223000037/0000898432-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$14.9 million"},{"label":"Net income","value":"$3.7 million"},{"label":"EPS","value":"$0.29 per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}